Immetas Therapeutics
Business Services · New Jersey, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
120 Eagle Rock Ave Ste 141, East Hanover...Phone Number
(973) 585-4793Website
www.immetas.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Immetas Therapeutics
Immetas is a biotechnology company that specializes in discovering and developing novel therapeutics aimed at modulating the innate immune system to address age-related cancers and inflammatory diseases. Their research is grounded in the understanding that chronic low-grade inflammation plays a critical role in aging and related health issues. The company employs a multistep approach that begins with clinical evidence to guide its therapeutic development. Immetas targets clients affected by chronic inflammation and age-related diseases, focusing on innovative solutions for cancer and autoimmunity.Explore more
Immetas Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immetas Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Immetas Therapeutics had a recent Job posting/layoffs
Immetas Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Immetas Therapeutics
Product Launch: Get notified when Immetas Therapeutics launches new products
Earning: See what the market has to say on Immetas Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Immetas Therapeutics has new funding data
Check out if Immetas Therapeutics is spiking on competitors!
Check if Immetas Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Immetas Therapeutics
Compare insights from companies similar to Immetas Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Immetas Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Immetas Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Immetas Therapeutics.
Immetas Therapeutics Tech Stack
A closer look at the technologies used by Immetas Therapeutics
See more technologies
Immetas Therapeutics News & Media
Immetas Therapeutics Announces Series A Financing to Advance Research on Inflammation Pathways in Aging and Develop Therapeutics for Cancer and Inflammatory Disease
EAST HANOVER, N.J.--(BUSINESS WIRE)--Immetas announces Series A financing to advance inflammation pathways research in aging and develop cancer, inflammatory disease therapeutics
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Immetas Therapeutics
Sign Up For FreeTo access detailed company insights
Immetas is a biotechnology company that specializes in discovering and developing novel therapeutics aimed at modulating the innate immune system to address age-related cancers and inflammatory diseases. Their research is grounded in the understanding that chronic low-grade inflammation plays a critical role in aging and related health issues. The... Read More
